Alexandra Gerlach, Associate Editor

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

Travelers face rising infectious disease risks, including measles, chikungunya, chagas disease, and others.

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards.

World Lymphoma Day highlights the rising prevalence of lymphoma and innovative treatments, emphasizing the role of pharmacists in patient care.

A fatal pediatric measles case in Los Angeles highlights the urgent need for MMR vaccination to protect vulnerable children from severe complications.

Pharmacists play a crucial role in managing myelofibrosis, enhancing patient education, adherence, and financial navigation for optimal care.

Experts at the ASTCT Gene Therapy Summit discussed the multifaceted nature of the gene therapy process for patients with sickle cell disease.

GLSI-100 shows promise in preventing HER2-positive breast cancer recurrence after standard therapy.

Florida's Surgeon General's plan to eliminate school vaccine mandates raises concerns about measles outbreaks and declining vaccination rates.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the management of hematologic and non-hematologic toxicities in cancer patients, emphasizing the importance of proactive monitoring and collaboration between clinicians and pharmacists.

HHS and Robert F. Kennedy Jr prepare to unveil a report linking Tylenol use in pregnancy to autism, despite inconsistent study findings.

Research reveals how aging impacts flu severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.

Patritumab deruxtecan shows promising efficacy in HR+/HER2– metastatic breast cancer, meeting key trial end points and highlighting its potential for advanced treatment.

In combination with lipid-lowering therapy, inclisiran allowed patients with hypercholesterolemia to reach their low-density lipoprotein cholesterol (LDL-C) goals without associated muscle-related adverse events.

Experts discuss radon—the second leading cause of lung cancer.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the challenges of managing myelofibrosis, from its heterogeneity and symptom burden to limited curative options.

Health officials warn of rising Chagas disease cases in the US, linked to kissing bugs and the parasite Trypanosoma cruzi, urging public awareness.

New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

GLP-1 medications like semaglutide and tirzepatide significantly lower heart failure hospitalization risks, expanding treatment options for obesity-related conditions.

Zongertinib promises significant advancements in patient care.

New research reveals that women on beta-blockers post-heart attack face a 45% higher risk of serious health issues compared with men.

Women using depot medroxyprogesterone acetate face a significantly higher risk of meningioma, especially with long-term use or starting after age 31.

Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared with intravenous administration, enhancing patient outcomes.

Fast-melt tablets (FMT) in drug delivery enhanced patient adherence and therapeutic response.

Rilzabrutinib gained FDA approval as the first BTK inhibitor for chronic immune thrombocytopenia, offering new hope for patients with persistent symptoms.

The subcutaneous injection for maintenance treatment enhances accessibility and reduces infusion time for patients.

Explore the impact of the Inflation Reduction Act on community oncology practices and discover how new legislation aims to protect patient access to care.

Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.